Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Srikanth Bellary

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Evidence-Based Medicine|March 24, 2011
For type 2 diabetes poorly controlled by metformin monotherapy, the addition of any non-insulin antidiabetic drug reduces HbA1c to a similar extent, but with differing effects on weight and hypoglycaemic riskSrikanth Bellary
The Lancet. Diabetes & Endocrinology|December 3, 2021
The changing character of diabetes complicationsSrikanth Bellary
The Lancet. Diabetes & Endocrinology|August 9, 2024
Implementing type 2 diabetes remission interventions in the real world: what have we learnt?Srikanth Bellary
The Lancet. Healthy Longevity|April 1, 2023
SGLT2 inhibitors in older adults: overcoming the age barrierSrikanth Bellary, Anthony H Barnett
Diabetes & Vascular Disease Research|December 13, 2006
Inhaled insulin (Exubera): Combining efficacy and convenienceSrikanth Bellary, Anthony H Barnett
The Lancet. Diabetes & Endocrinology|May 7, 2023
Insulin icodec: evolution or revolution in diabetes therapy?Srikanth Bellary, Anthony H Barnett
Current Diabetes Reports|January 5, 2008
Selection and education of patients for inhaled insulinSrikanth Bellary, Anthony H Barnett
The Lancet. Diabetes & Endocrinology|June 14, 2016
Preventing hypoglycaemia: an elusive questAlan J Sinclair, Srikanth Bellary
Current Diabetes Reports|February 3, 2022
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney DiseaseClifford J Bailey, Caroline Day, Srikanth Bellary
Biogerontology|February 22, 2016
Innovative biomarkers for predicting type 2 diabetes mellitus: relevance to dietary management of frailty in older adultsJohn Ikwuobe, Srikanth Bellary, Helen R Griffiths
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Evidence-Based Medicine|March 24, 2011
For type 2 diabetes poorly controlled by metformin monotherapy, the addition of any non-insulin antidiabetic drug reduces HbA1c to a similar extent, but with differing effects on weight and hypoglycaemic riskSrikanth Bellary
The Lancet. Diabetes & Endocrinology|December 3, 2021
The changing character of diabetes complicationsSrikanth Bellary
The Lancet. Diabetes & Endocrinology|August 9, 2024
Implementing type 2 diabetes remission interventions in the real world: what have we learnt?Srikanth Bellary
The Lancet. Healthy Longevity|April 1, 2023
SGLT2 inhibitors in older adults: overcoming the age barrierSrikanth Bellary, Anthony H Barnett
Diabetes & Vascular Disease Research|December 13, 2006
Inhaled insulin (Exubera): Combining efficacy and convenienceSrikanth Bellary, Anthony H Barnett
The Lancet. Diabetes & Endocrinology|May 7, 2023
Insulin icodec: evolution or revolution in diabetes therapy?Srikanth Bellary, Anthony H Barnett
Current Diabetes Reports|January 5, 2008
Selection and education of patients for inhaled insulinSrikanth Bellary, Anthony H Barnett
The Lancet. Diabetes & Endocrinology|June 14, 2016
Preventing hypoglycaemia: an elusive questAlan J Sinclair, Srikanth Bellary
Current Diabetes Reports|February 3, 2022
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney DiseaseClifford J Bailey, Caroline Day, Srikanth Bellary
Biogerontology|February 22, 2016
Innovative biomarkers for predicting type 2 diabetes mellitus: relevance to dietary management of frailty in older adultsJohn Ikwuobe, Srikanth Bellary, Helen R Griffiths
Pageof 7